Eliska Zelinkova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eliska Zelinkova has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Barbora Jankovicova
Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Pardubice, Czech Republic
1 shared publication- Jan Lakota
Centre of Experimental Medicine, Slovak Academy of Sciences
1 shared publication - Lenka Minichová
Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, Dúbravská cesta 9, 845 05 Bratislava, Slovakia
1 shared publication - Lucie Korecká
Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Pardubice, Czech Republic
1 shared publication - Ludovit Skultety
Department of Rickettsiology, Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, Dúbravská Cesta 9, 84505 Bratislava, Slovakia
1 shared publication - Maksym Danchenko
Institute of Chemistry of the Slovak Academy of Sciences, Bratislava, Slovakia, Slovakia
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by Wiley in Mediators of Inflammation
- Vol. 2024 (1) , 9981131
Inhibitory Effect of Human Anti‐CA I Autoantibodies and Development of Monoclonal Antibody mAb 2B8 Targeting Carbonic Anhydrase I
Spontaneous tumor regression is a recognized phenomenon across various cancer types. Recent research emphasizes the alterations in autoantibodies against carbonic anhydrase I (CA I) (anti‐CA I) levels as potential prognostic markers for various malignancies. Particularly, autoantibodies targeting CA I and II appear to induce cellular damage by inhibiting their respective protein’s catalytic functions. Our study illuminates the profound impact of anti‐CA I autoantibodies from patient serum on the esterase activity of human CA I, exhibiting inhibitory effects akin to the acetazolamide inhibitor. Concurrently, our newly synthesized mouse monoclonal IgG antibody, mAb 2B8, against human CA I showcased a potent inhibitory action. An in‐depth exploration into mAb 2B8′s binding dynamics with its target enzyme was undertaken. Leveraging epitope extraction and phage display library techniques, we identified the amino acid sequence DFWTYP (positions 191–196 of CA I) as crucial for mAb 2B8′s interaction. In 3‐D structural analysis, this sequence is spatially adjacent to a previously identified epitope (DFWTYP) that interacts with patient‐derived autoantibodies. Critically, mAb 2B8 demonstrated an ability to infiltrate eukaryotic cells, engaging specifically with its intracytoplasmic target. This positions mAb 2B8 as a promising model for future studies aimed at tumor cell eradication.
- 1 January 2024
- Published by Wiley in Mediators of Inflammation
- Vol. 2024 (1) , 9981131
Open AccessInhibitory Effect of Human Anti‐CA I Autoantibodies and Development of Monoclonal Antibody mAb 2B8 Targeting Carbonic Anhydrase I
Spontaneous tumor regression is a recognized phenomenon across various cancer types. Recent research emphasizes the alterations in autoantibodies against carbonic anhydrase I (CA I) (anti‐CA I) levels as potential prognostic markers for various malignancies. Particularly, autoantibodies targeting CA I and II appear to induce cellular damage by inhibiting their respective protein’s catalytic functions. Our study illuminates the profound impact of anti‐CA I autoantibodies from patient serum on the esterase activity of human CA I, exhibiting inhibitory effects akin to the acetazolamide inhibitor. Concurrently, our newly synthesized mouse monoclonal IgG antibody, mAb 2B8, against human CA I showcased a potent inhibitory action. An in‐depth exploration into mAb 2B8′s binding dynamics with its target enzyme was undertaken. Leveraging epitope extraction and phage display library techniques, we identified the amino acid sequence DFWTYP (positions 191–196 of CA I) as crucial for mAb 2B8′s interaction. In 3‐D structural analysis, this sequence is spatially adjacent to a previously identified epitope (DFWTYP) that interacts with patient‐derived autoantibodies. Critically, mAb 2B8 demonstrated an ability to infiltrate eukaryotic cells, engaging specifically with its intracytoplasmic target. This positions mAb 2B8 as a promising model for future studies aimed at tumor cell eradication.